Formulation and development of release modulated colon targeted system of meloxicam for potential application in the prophylaxis of colorectal cancer

Drug Delivery

Volumn 18, Issue 4, 2011, Pages 281-293

  Patel, Mayur M ^a   Amin, Avani F ^a  

^a NIRMA UNIVERSITY   (India)

Author keywords

buffering agent; colon specific delivery; COX 2; polyethylene oxide; roentgenography

Indexed keywords

ACRYLIC ACID METHYL ESTER; ETHYL CELLULOSE; MACROGOL; MELOXICAM; METHACRYLIC ACID; METHACRYLIC ACID METHYL ESTER;

ARTICLE; CANCER PREVENTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ABSORPTION; DRUG COATING; DRUG DEVELOPMENT; DRUG FORMULATION; DRUG RELEASE; DRUG SOLUBILITY; NONHUMAN; PH; PRIORITY JOURNAL; RADIOGRAPHY; TABLET; TABLET FORMULATION;

ANIMALS; CELLULOSE; CHEMISTRY, PHARMACEUTICAL; COLON; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROGEN-ION CONCENTRATION; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; RABBITS; SOLUBILITY; TABLETS; THIAZINES; THIAZOLES;

EID: 79953250247     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2010.538447     Document Type: Article

References (49)

1. Ahmedin, J., Rebecca, S., Elizabeth, W., Yongping, H., Jiaquan, X., Michael, J.T. (2009). Cancer Statistics. CA Cancer J Clin. 59:225-49.
2. Ahmedin, J., Rebecca, S., Elizabeth, W., Yongping, H., Jiaquan, X., Michael, J.T. (2009). Cancer Statistics. CA Cancer J Clin. 59:225-49. Arber, N., Levin, B. (2005). Chemoprevention of colorectal cancer: Ready for routine use? Recent Results Cancer Res. 166:213-30.
3. Asghar, L.F., Chandran, S. (2008). Design and evaluation of matrices of Eudragit with polycarbophil and carbopol for colon specific delivery. J Drug Target. 16:741-57.
4. H-dependent polymers for colonic targeting. Int J Pharm. 91:241-5. (Pubitemid 23159828)
5. Ayakawa, S., Shibamoto, Y., Sugie, C., Ito, M., Ogino, H., Tomita, N., Kumagai, M., Murakami, H., Sawa, H. (2009). Antitumor effects of acyclooxygenase-2 inhibitor, meloxicam, alone and in combination with radiation and/or 5-fluorouracil in cultured tumor cells. Mol Med Repor. 2:621-5.
6. H- and time-based multiunit colonic drug delivery system. Aliment Pharmacol Ther. 20:347-53.
7. Churchill, L., Graham, A.G., Shih, C.K., Pauletti, D., Farina, P.R., Grob, P.M. (1996). Selective inhibition of human cyclooxygenase-2 by meloxicam. Inflammopharmacology. 4:125-35. (Pubitemid 26153204)
8. DuBois, R.N., Giardiello, F.M., Smalley, W.E. (1996). Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention. Gastroenterol Clin North Am. 25:773-91. (Pubitemid 27022915)
9. Fukui, E., Miyamura, N., Uemura, K., Kobayashi, M. (2000). Preparation of enteric coated timed release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int J Pharm. 204:7-15.
10. H-dependent colon specific drug delivery for orally administered diclofenac sodium and 5 aminosalicylic acid. World J Gastroenterol. 10:1769-74.
11. Gao, C., Huang, J., Jiao, Y., Shan, L., Liu, Y., Li, Y., Mei, X. (2006). In vitro release and in vivo absorption in beagle dogs of meloxicam from Eudragit® FS 30 D coated pellets. Int J Pharm. 322:104-12. (Pubitemid 44331530)
12. Ghorab, M.M., Abdel-Salam, H.M., El-Sayad, M.A., Mekhel, M.M. (2004). Tablet formulation containing meloxicam and β-cyclodextrin: Mechanical characterization and bioavailability evaluation. AAPS PharmSciTech. Available online at: http://www.aapspharmscitech.org/view.asp?art=pt050459, accessed 7 June 2008.
13. Ghosh, M.N. (2008). Fundamentals of experimental pharmacology. In: Ghosh, S.K., et al., eds. Kolkata, India:1071-1076.
14. Giardiello, F.M., Offerhaus, G.J.A., DuBois, R.N. (1995). The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention. Eur J Cancer. 31:1071-6.
15. Gidenne, T., Lebas, F. (2006). Feeding behavior in rabbits. In: Bels, V., ed. Feeding in domestic vertebrates: From structure to behavior. Oxfordshire: CABI Publishing, 179-94.
16. Giovannucci, E., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Ascherio, A., Willett, W.C. (1994). Aspirin use and the risk of colorectal cancer and adenoma in male health professionals. Ann Intern Med. 121:241-6.
17. Goldman, A.P., Williams, C.S., Sheng, H., Lamps, L.W., Williams, V.P., Pairet, M., Morrow, J.D., Dubois, R.N. (1998). Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis. 19:2195-9. (Pubitemid 29010262)
18. Harris, R.E., Beebe-Donk, J., Alshafie, G.A. (2007). Cancer chemoprevention by cyclooxygenase 2 (COX-2) blockade. In: Harris, R.E., ed. Inflammation in the pathogenesis of chronic diseases: The COX-2 controversy. New York: Springer Science, 193-212. http://www.pharma-polymers.com, accessed 9 February 2009.
19. Huyghebaert, N., Vermeire, A., Remon, J.P. (2005). In vitro evaluation of coating polymers for enteric coating and human ileal targeting. Int J Pharm. 298:26-37. (Pubitemid 40828326)
20. Ishikawa, T., Koizumi, N., Mukai, B., Utoguchi, N., Fujii, M., Matsumoto, M., Endo, H., Shirotake, S., Watanabe, Y. (2001). Pharmacokinetics of acetaminophen from rapidly disintegrating compressed tablet prepared using microcrystalline cellulose (PH-M-06) and spherical sugar granules. Chem Pharm Bull. 49:230-2. (Pubitemid 32174661)
21. H-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit L100-55 and Eudragit S100 combinations. J Control Rel. 58:215-22. (Pubitemid 29112892)
22. H- dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit® L100 and Eudragit® S100 combinations. Drug Dev Ind Pharm. 26:549-54. (Pubitemid 30225633)
23. Krishnaiah, Y.S., Bhaskar Reddy, P.R., Satyanarayana, V., Karthikeyan, R.S. (2002). Studies on the development of oral colon targeted drug delivery systems for metronidazole in the treatment of amoebiasis. Int J Pharm. 236:43-55. (Pubitemid 34219372)
24. Hand time-dependent oral microparticles to optimize budesonide delivery to ileum and colon. Int J Pharm. 338:238-47. (Pubitemid 46777247)
25. H dependent colon specific, pulsatile delivery of theophylline for nocturnal asthma. Int J Pharm. 328:49-56. (Pubitemid 44827555)
26. Mathews, B.R. (1999). Regulatory aspects of stability testing in Europe. Drug Dev Ind Pharm. 25:831-56.
27. H and bacteria as physiological trigger mechanisms for colonic targeting in man. J Control Rel. 130:154-60.
28. Naruse, T., Nishida, Y., Hosono, K., Ishiguro, N. (2006). Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes. Carcinogenesis. 27:584-92. (Pubitemid 43378898)
29. H in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs. Gut. 48:571-7. (Pubitemid 32234805)
30. O'Neil, M.J. (2006). The Merck Index: An encyclopedia of chemicals, drugs and biologicals. New Jersey: Merck and Co., INC.
31. Patel, M., Shah, T., Amin, A. (2007). Therapeutic opportunities in colon specific drug delivery system. Crit Rev Ther Drug Carrier Syst. 24:147-202.
32. H-dependent colon targeted drug delivery system. Pharm Dev Technol. 14: 62-9.
33. Philip, A., Pathak, K. (2008a). Wet process-induced phase-transited drug delivery system: A means for achieving osmotics, controlled and level A IVIVC for poorly water soluble drug. Drug Dev Ind Pharm. 34:735-43. (Pubitemid 351962346)
34. Philip, A.K., Pathak, K. (2008b). In situ formed phase transited drug delivery system of ketoprofen for achieving osmotic, controlled and level A in vitro in vivo correlation. Indian J Pharm Sci. 70: 745-53.
35. H- and Time-Dependent system for colonic drug delivery. Drug Dev Ind Pharm. 29: 661-7. (Pubitemid 36835159)
36. Ricchi, P., Zarrilli, R., Di Palma, A., Acquaviva, A.M. (2003). Nonsteroidal anti-inflammatory drugs in colorectal cancer: From prevention to therapy. Br J Cancer. 88:803-7. (Pubitemid 36520863)
37. H-independent drug release of an extremely poorly soluble weakly acidic drug from multiparticulate extended release formulations. Eur J Pharm Biopharm. 65:78-84. (Pubitemid 44827687)
38. Sangalli, M.E., Maroni, A., Foppoli, A., Zema, L., Giordano, F., Gazzaniga, A. (2004). Different HPMC viscosity grades as coating agents for an oral time and / or site-controlled delivery system: A study on process parameters and in vitro performances. Eur J Pharm Sci. 22:469-76. (Pubitemid 38953906)
39. Sangalli, M.E., Maroni, A., Zema, L., Busetti, C., Giordano, F., Gazzaniga, A. (2001). In vitro and in vivo evaluation of an oral system for time and / or site-specific drug delivery.J Control Rel. 73:103-10. (Pubitemid 32409351)
40. Sano, H., Kawahito, Y., Wilder, R.L., Hashiramoto, A., Mukai, S., Asai, K., Kimura, S., Kato, H., Kondo, M., Hla, T. (1995). Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 55:3785-9.
41. Seong-Hee, K., Choi, G.J., Lee, J.H., Yoon, A.H., Soo-Jeong, L., Kim, S.H. (2008). Differential effects of selective cyclooxygenase-2 inhibitors in inhibiting proliferation and induction of apoptosis in oral squamous cell carcinoma. Oncol Rep. 19:425-33. (Pubitemid 351176104)
42. Sheng, H., Shao, J., Kirkland, S.C., Isakson, P., Coffey, R.J., Morrow, J., Beauchamp, R.D., DuBois, R.N. (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest. 99:2254-9. (Pubitemid 27203783)
43. Steed, K.P., Hooper, G., Monti, N., Benedetti, M.S., Fornasini, G., Wilding, I.R. (1997). The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system ("TIME CLOCK®" system). J Control Rel. 49:115-22.
44. Tsubouchi, Y., Mukai, S., Kawahito, Y., Yamada, R., Kohno, M., Inoue, K., Sano, H. (2000b). Meloxicam inhibits the growth of non-small cell lung cancer. Anticancer Res. 20:2867-72.
45. Tsubouchi, Y., Sano, H., Yamada, R., Hashiramoto, A., Kohno, M., Kusaka, Y., Kondo, M. (2000a). Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Eur J Pharmacol. 395:255-63. (Pubitemid 30254376)
46. Vijayalakshmi, P., Devi, V.K., Devi, K., Benson, M.K., Srinagesh, S. (2008). Formulation development and in vivo characterization of solubility enhanced gliclazide tablets. Curr trends Biotech Pharm. 2:456-61.
47. Wei, H., Qing, D., De-Ying, C., Bai, X., Li-Fang, F. (2008). In vitro and in vivo studies of pectin/ethylcellulose film coated pellets of 5-fluorouracil for colonic targeting. J Pharm Pharmacol. 60: 35-44.
48. Whittle, B.J.R. (2000). COX-1 and COX-2 products in the gut: Therapeutic impact of COX-2 inhibitors. Gut. 47:320-5. www.ich.org. Accessed 15 August 2009.
49. Zhang, N., Tao, K., Huang, T. (2007). Effects of meloxicam on vascular endothelial growth factor and angiopoietin-2 expression in colon carcinoma cell line HT-29. J Huazhong Univ Sci Tech Med Sci. 27:399-402.